Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Optimising the management of patients with multiple myeloma in Spain: A measurement of the social return on investment

Optimising the management of patients with multiple myeloma in Spain: A measurement of the social... AbbreviationsAEALAsociación Española de Afectados de Linfoma, Mieloma y Leucemia (Spanish Association of People Affected by Lymphoma, Myeloma and Leukaemia)CEMMPComunidad Española de Pacientes con Mieloma Múltiple (Spanish Community of Multiple Myeloma Patients)CHEERSConsolidated Health Economic Evaluation Reporting StandardsCRABCalcium level, renal dysfunction, anaemia and destructive bone lesionsDDiagnosisEDHTEmergency Department, Hospitalisation and TransplantF/UFollow‐upFACT‐MMFunctional Assessment of Cancer for Therapy‐Multiple MyelomaGEPACGrupo Español de Pacientes con Cáncer (Spanish Group of Cancer Patients)MMillionMMMultiple myelomaMWTMultidisciplinary Working TeamSSupportSEEOSociedad Española de Enfermería Oncológica (Spanish Society of Oncology Nursing)SEFH‐GEDEFOSociedad Española de Farmacia Hospitalaria‐Grupo Español para el Desarrollo de la Farmacia Oncológica (Spanish Society of Hospital Pharmacy‐Spanish Group for the Development of the Oncology Pharmacy)SEHHSociedad Española de Hematología y Hemoterapia (Spanish Society of Haematology and Hemotherapy)SEMERGENSociedad Española de Médicos de Atención Primaria (Spanish Society of Primary Care Physicians)SNHSSpanish National Health SystemSROISocial Return on InvestmentINTRODUCTIONMultiple myeloma (MM) is a cancer of the plasma cells of the bone marrow (International Myeloma Foundation, 2019) that accounts for 1% of all cancers and around 10% of all haematological malignancies (Moreau et al., 2017). In Spain, the annual incidence rate is 7.0/100,000 inhabitants, and the annual mortality rate is 4.6/100,000 inhabitants, which resulted in 3,261 new cases and 2,114 deaths related to MM in 2018 (Ferlay et al., 2018). Progression of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Cancer Care Wiley

Optimising the management of patients with multiple myeloma in Spain: A measurement of the social return on investment

Download PDF
9 pages

Loading next page...
 
/lp/wiley/optimising-the-management-of-patients-with-multiple-myeloma-in-spain-a-RQBNJz1Evo
Publisher
Wiley
Copyright
© 2022 John Wiley & Sons Ltd
ISSN
0961-5423
eISSN
1365-2354
DOI
10.1111/ecc.13706
Publisher site
See Article on Publisher Site

Abstract

AbbreviationsAEALAsociación Española de Afectados de Linfoma, Mieloma y Leucemia (Spanish Association of People Affected by Lymphoma, Myeloma and Leukaemia)CEMMPComunidad Española de Pacientes con Mieloma Múltiple (Spanish Community of Multiple Myeloma Patients)CHEERSConsolidated Health Economic Evaluation Reporting StandardsCRABCalcium level, renal dysfunction, anaemia and destructive bone lesionsDDiagnosisEDHTEmergency Department, Hospitalisation and TransplantF/UFollow‐upFACT‐MMFunctional Assessment of Cancer for Therapy‐Multiple MyelomaGEPACGrupo Español de Pacientes con Cáncer (Spanish Group of Cancer Patients)MMillionMMMultiple myelomaMWTMultidisciplinary Working TeamSSupportSEEOSociedad Española de Enfermería Oncológica (Spanish Society of Oncology Nursing)SEFH‐GEDEFOSociedad Española de Farmacia Hospitalaria‐Grupo Español para el Desarrollo de la Farmacia Oncológica (Spanish Society of Hospital Pharmacy‐Spanish Group for the Development of the Oncology Pharmacy)SEHHSociedad Española de Hematología y Hemoterapia (Spanish Society of Haematology and Hemotherapy)SEMERGENSociedad Española de Médicos de Atención Primaria (Spanish Society of Primary Care Physicians)SNHSSpanish National Health SystemSROISocial Return on InvestmentINTRODUCTIONMultiple myeloma (MM) is a cancer of the plasma cells of the bone marrow (International Myeloma Foundation, 2019) that accounts for 1% of all cancers and around 10% of all haematological malignancies (Moreau et al., 2017). In Spain, the annual incidence rate is 7.0/100,000 inhabitants, and the annual mortality rate is 4.6/100,000 inhabitants, which resulted in 3,261 new cases and 2,114 deaths related to MM in 2018 (Ferlay et al., 2018). Progression of

Journal

European Journal of Cancer Care – Wiley

Published: Nov 1, 2022

Keywords: cost–benefit analysis; disease management; haematological malignancies; multiple myeloma; social return on investment (SROI); Spanish national health system

References

  • Informe 2015 de Necesidades de Los Pacientes Con Mieloma Múltiple y Sus Familiares En España
  • Informe de Recomendaciones Para La Atención de Calidad Del Mieloma Múltiple
  • Healthcare resource utilisation associated with skeletal‐related events in European patients with multiple myeloma: Results from a prospective, multinational, observational study
    Ashcroft, J.; Duran, I.; Hoefeler, H.; Lorusso, V.; Lueftner, D.; Campioni, M.; Intorcia, M.; Bahl, A.
  • What about the issues in using social return on investment as an evaluation tool?
    Banke‐Thomas, A.
  • Social return on investment (SROI) methodology to account for value for money of public health interventions: A systematic review
    Banke‐Thomas, A. O.; Madaj, B.; Charles, A.; Broek, N.
  • Assessing value‐for‐money in maternal and newborn health
    Banke‐Thomas, A.; Madaj, B.; Kumar, S.; Ameh, C.; Broek, N.
  • Multiple myeloma and infections: A population‐based study on 9253 multiple myeloma patients
    Blimark, C.; Holmberg, E.; Mellqvist, U.‐H.; Landgren, O.; Björkholm, M.; Hultcrantz, M.; Kjellander, C.; Turesson, I.; Kristinsson, S. Y.
  • The risk of infections in multiple myeloma before and after the advent of novel agents: A 12‐year survey
    Brioli, A.; Klaus, M.; Sayer, H.; Scholl, S.; Ernst, T.; Hilgendorf, I.; Scherag, A.; Yomade, O.; Schilling, K.; Hochhaus, A.; Mügge, L.‐O.; Lilienfeld‐Toal, M.
  • Multidisciplinary approach to psoriasis in the Spanish National Health System: A social return on investment study
    Carretero, G.; Moreno, D.; Domínguez, A. G.; Trigos, D.; Ledesma, A.; Sarquella, E.; Merino, M.; Blanch, C.
  • Cuantificando El Beneficio de La Sustitución Por Vinorelbina Oral En Los Pacientes Susceptibles de Tratamiento Con Vinorelbina. Estudio Del Retorno Social de La Inversión
    Castro Carpeño, J.; Pérez, J. L. F.; Barragán, P. L.; Dols, M. Á. C.; Gil, J. M.; Mena, A. C.; Puentes, Á. F.; Palomo, A. G.; Mateu, M. M.; Soler, M. J. C.; Saiz, M. Á. P.; García, J. P.; Pinyol‐i‐Villena, C.
  • Methods for the economic evaluation of health care programmes
    Drummond, M. F.; Sculpher, M. J.; Claxton, K.; Stoddart, G. L.; Torrance, G. W.; Stoddart, G. L.
  • Social return on investment
    Emerson, J.; Cabaj, M.
  • Situación actual y retos del mieloma múltiple en España 2018
  • Trends in overall survival and costs of multiple myeloma, 2000–2014
    Fonseca, R.; Abouzaid, S.; Bonafede, M.; Cai, Q.; Parikh, K.; Cosler, L.; Richardson, P.
  • Social value of a nutritional counselling and support program for breastfeeding in urban poor settings, Nairobi
    Goudet, S.; Griffiths, P. L.; Wainaina, C. W.; Macharia, T. N.; Wekesah, F. M.; Wanjohi, M.; Muriuki, P.; Kimani‐Murage, E.
  • Myeloma: Patient accounts of their pathways to diagnosis
    Howell, D. A.; Hart, R. I.; Smith, A. G.; Macleod, U.; Patmore, R.; Cook, G.; Roman, E.
  • Consolidated health economic evaluation reporting standards (CHEERS) statement
    Husereau, D.; Drummond, M.; Petrou, S.; Carswell, C.; Moher, D.; Greenberg, D.; Augustovski, F.; Briggs, A. H.; Mauskopf, J.; Loder, E.; Task Force, C. H. E. E. R. S.
  • Productivity losses in patients with newly diagnosed multiple myeloma following stem cell transplantation and the impact of maintenance therapy
    Jackson, G.; Galinsky, J.; Alderson, D. E. C.; D'Souza, V. K.; Buchanan, V.; Dhanasiri, S.; Walker, S.
  • Older people going online: Its value and before‐after evaluation of volunteer support
    Jones, R. B.; Ashurst, E. J.; Atkey, J.; Duffy, B.
  • Social return on investment analysis of an art Group for people with dementia
    Jones, C.; Edwards, R. T.; Windle, G.
  • Patient reported outcomes in optimizing myeloma patients' health‐related quality of life
    King, T. A.; King, M. T.; White, K. J.
  • Healthcare resource utilization and cost of patients with multiple myeloma in Germany: A retrospective claims data analysis
    Kocaata, Z.; Wilke, T.; Fischer, F.; Welte, R.; Einsele, H.
  • Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs
    Kolovos, S.; Nador, G.; Kishore, B.; Streetly, M.; Rabin, N. K.; Chantry, A. D.; Yong, K.; Ashcroft, J.; Bowcock, S.; Drayson, M. T.; Ramasamy, K.; Prieto‐Alhambra, D.; Cyrus, C.; Kassim Javaid, M.; Pinedo‐Villanueva, R.
  • Continued improvement in survival in multiple myeloma: Changes in early mortality and outcomes in older patients
    Kumar, S. K.; Dispenzieri, A.; Lacy, M. Q.; Gertz, M. A.; Buadi, F. K.; Pandey, S.; Kapoor, P.; Dingli, D.; Hayman, S. R.; Leung, N.; Lust, J.; McCurdy, A.; Russell, S. J.; Zeldenrust, S. R.; Kyle, R. A.; Rajkumar, S. V.
  • “It's not just camp!”: Understanding the meaning of children's cancer camps for children and families
    Laing, C. M.; Moules, N. J.
  • Social return on investment for patient treated by continuous ambulatory peritoneal Dialysis: A case study in Ubon Ratchathani Province, Thailand
    Lophongpanit, P.; Tongsiri, S.; Thongprasert, N.
  • Return on investment of public health interventions: A systematic review
    Masters, R.; Anwar, E.; Collins, B.; Cookson, R.; Capewell, S.
  • Determinants of hospital death in haematological cancers: Findings from a qualitative study
    McCaughan, D.; Roman, E.; Smith, A. G.; Garry, A.; Johnson, M.; Patmore, R.; Howard, M.; Howell, D. A.
  • Improving rheumatoid arthritis management within the Spanish National Health System: A social return on investment study
    Merino, M.; Ivanova, Y.; Lorenzo, T. M.; Hidalgo‐Vega, Á.
  • Valor social de la mejora del abordaje del mieloma múltiple en el Sistema Nacional de Salud’. in 39 Jornadas de Economía de la Salud ‐ La transparencia es saludable ‐ La importancia de la rendición de cuentas en Sanidad
    Merino, M.; Ivanova, Y.; Maravilla, P.; Hidalgo‐Vega, Á.
  • The social return on Investment of a new approach to heart failure in the Spanish National Health System
    Merino, M.; Jiménez, M.; Manito, N.; Casariego, E.; Ivanova, Y.; González‐Domínguez, A.; Saturnino, M. S.; Hidalgo‐Vega, Á.; Blanch, C.
  • A social return on investment analysis of improving the management of chronic obstructive pulmonary disease within the Spanish National Healthcare System
    Merino, M.; Lorenzo, T. M.; Maravilla‐Herrera, P.; Ancochea, J.; Sáenz, J. T. G.; Hass, N.; Molina, J.; Peces‐Barba, G.; Trapero‐Bertran, M.; Carrero, J. A. T.; Hidalgo‐Vega, Á.
  • Social value of a set of proposals for the ideal approach of multiple sclerosis within the Spanish National Health System: A social return on investment study
    Moral Torres, E.; Fernández, Ó. F.; Rueda, P. C.; Ruiz‐Beato, E.; Pérez, E. E.; Estrada, R. M.; Gómez‐García, T.; Jiménez, M.; Hidalgo‐Vega, Á.; Merino, M.
  • Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow‐up
    Moreau, P.; San Miguel, J.; Sonneveld, P.; Mateos, M. V.; Zamagni, E.; Avet‐Loiseau, H.; Hajek, R.; Dimopoulos, M. A.; Ludwig, H.; Einsele, H.; Zweegman, S.; Facon, T.; Cavo, M.; Terpos, E.; Goldschmidt, H.; Attal, M.; Buske, C.
  • Social return on investment—Development and convergence
    Nicholls, J.
  • A guide to social return on investment
    Nicholls, J.; Lawlor, E.; Neitzert, E.; Goodspeed, T.
  • Distress and unmet needs during treatment and quality of life in early Cancer survivorship: A longitudinal study of haematological cancer patients
    Oberoi, D. V.; White, V. M.; Seymour, J. F.; Miles Prince, H.; Harrison, S.; Jefford, M.; Winship, I.; Hill, D. J.; Bolton, D.; Millar, J.; Doo, N. W.; Kay, A.; Giles, G.
  • Differences in the economic valuation and determining factors of informal care over time: The case of blood cancer
    Ortega‐Ortega, M.; Montero‐Granados, R.; Jiménez‐Aguilera, J. d. D.
  • Value in myeloma care: Myth or reality
    Ouchveridze, E.; Berger, K.; Mohyuddin, G. R.
  • Revised international staging system for multiple myeloma: A report from international myeloma working group
    Palumbo, A.; Avet‐Loiseau, H.; Oliva, S.; Lokhorst, H. M.; Goldschmidt, H.; Rosinol, L.; Richardson, P.; Caltagirone, S.; Lahuerta, J. J.; Facon, T.; Bringhen, S.; Gay, F.; Attal, M.; Passera, R.; Spencer, A.; Offidani, M.; Kumar, S.; Musto, P.; Lonial, S.; Moreau, P.
  • Patient perceived financial burden in haematological malignancies: A systematic review
    Parker, C.; Berkovic, D.; Ayton, D.; Zomer, E.; Liew, D.; Wei, A.
  • El Retorno Económico y Social de La E‐Interconsulta de Cardiología En El Área de Vigo
    Piñeiro, D.; Goretti, M. C. S. C.; Gil, C. P.; Paredes‐Galán, E.; Ruíz, R. G.; Sestayo, R. L.; Sellera, C. G.; Lamas, M.
  • The experiences and needs of primary family caregivers of patients with multiple myeloma: A qualitative analysis
    Quiñoa‐Salanova, C.; Porta‐Sales, J.; Monforte‐Royo, C.; Edo‐Gual, M.
  • Prevalence of symptoms in patients with multiple myeloma: A systematic review and meta‐analysis
    Ramsenthaler, C.; Kane, P.; Gao, W.; Siegert, R. J.; Edmonds, P. M.; Schey, S. A.; Higginson, I. J.
  • International survey—Myeloma treatment compliance 2009
    Rhein‐Main, M. G.
  • International survey—Myeloma treatment side effects and unmet patient needs 2009
    Rhein‐Main, M. G.
  • Perceived need for information of patients with Haematological malignancies: A literature review
    Rood, J. A. J.; Eeltink, C. M.; Zuuren, F. J.; Verdonck‐de Leeuw, I. M.; Huijgens, P. C.
  • Estimating the value of volunteer‐assisted community‐based aging services: A case example
    Scharlach, A. E.
  • The impact of improving Haemophilia a management within the Spanish National Healthcare System: A social return on investment analysis
    Soto, I.; Mateo, J.; García‐Diego, D.‐A.; Gil, B.; Ruiz‐Beato, E.; Ivanova, Y.; Lorenzo, T. M.; Maravilla‐Herrera, P.; Hidalgo‐Vega, Á.; Merino, M.
  • Quantifying the benefits of peer support for people with dementia: A social return on investment (SROI) study
    Willis, E.; Semple, A. C.; Waal, H.